Zacks Investment Research Analysts Increase Earnings Estimates for Antares Pharma, Inc. (ATRS)
Antares Pharma, Inc. (NASDAQ:ATRS) – Research analysts at Zacks Investment Research upped their FY2018 EPS estimates for Antares Pharma in a research note issued to investors on Wednesday. Zacks Investment Research analyst J. Vandermosten now anticipates that the specialty pharmaceutical company will post earnings of $0.04 per share for the year, up from their prior forecast of $0.03. Zacks Investment Research also issued estimates for Antares Pharma’s FY2019 earnings at $0.39 EPS.
Other analysts also recently issued reports about the company. Vetr raised Antares Pharma from a “hold” rating to a “buy” rating and set a $3.30 price target for the company in a research report on Wednesday, July 5th. Chardan Capital initiated coverage on Antares Pharma in a research report on Friday, June 23rd. They set a “buy” rating and a $5.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Antares Pharma in a research report on Friday, June 23rd. Piper Jaffray Companies set a $4.00 price target on Antares Pharma and gave the company a “buy” rating in a research report on Wednesday, July 26th. Finally, Raymond James Financial, Inc. initiated coverage on Antares Pharma in a research report on Thursday, April 20th. They set a “strong-buy” rating and a $4.30 price target for the company. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and two have given a strong buy rating to the stock. Antares Pharma presently has a consensus rating of “Buy” and an average price target of $3.83.
TRADEMARK VIOLATION WARNING: This story was posted by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.watchlistnews.com/zacks-investment-research-analysts-increase-earnings-estimates-for-antares-pharma-inc-atrs/1468717.html.
Shares of Antares Pharma (NASDAQ:ATRS) traded down 4.00% on Thursday, hitting $2.88. The stock had a trading volume of 701,700 shares. The company’s market capitalization is $449.06 million. Antares Pharma has a 52 week low of $1.01 and a 52 week high of $3.37. The company has a 50-day moving average of $3.15 and a 200 day moving average of $2.76.
Antares Pharma (NASDAQ:ATRS) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.01. Antares Pharma had a negative return on equity of 40.24% and a negative net margin of 34.27%. The company had revenue of $13.42 million during the quarter, compared to the consensus estimate of $12.99 million.
In other news, insider Fred M. Powell acquired 130,000 shares of Antares Pharma stock in a transaction on Friday, June 9th. The stock was acquired at an average cost of $2.79 per share, with a total value of $362,700.00. Following the completion of the acquisition, the insider now owns 331,434 shares in the company, valued at $924,700.86. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 11.60% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in ATRS. Alliancebernstein L.P. purchased a new position in shares of Antares Pharma during the second quarter valued at $119,000. Legal & General Group Plc purchased a new position in shares of Antares Pharma during the second quarter valued at $120,000. Credit Suisse AG purchased a new position in shares of Antares Pharma during the first quarter valued at $146,000. National Planning Corp raised its position in shares of Antares Pharma by 11.5% in the second quarter. National Planning Corp now owns 58,233 shares of the specialty pharmaceutical company’s stock valued at $186,000 after buying an additional 6,000 shares during the period. Finally, KCG Holdings Inc. raised its position in shares of Antares Pharma by 48.8% in the first quarter. KCG Holdings Inc. now owns 66,717 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 21,881 shares during the period. 31.70% of the stock is owned by institutional investors and hedge funds.
About Antares Pharma
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.